We are live on ! Find out more
BDTX icon

Black Diamond Therapeutics
BDTX

90 hedge funds and large institutions have $218M invested in Black Diamond Therapeutics in 2024 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 25 increasing their positions, 19 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

185% more call options, than puts

Call options by funds: $331K | Put options by funds: $116K

32% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 19

15% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 27

9% more capital invested

Capital invested by funds: $200M → $218M (+$18M)

6.89% more ownership

Funds ownership: 76.24% → 83.13% (+6.9%)

2% more funds holding

Funds holding: 88 → 90 (+2)

Holders
90
Holders Change
+2
Holders Change %
+2.27%
% of All Funds
1.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
31
Increased
25
Reduced
19
Closed
27
Calls
$331K
Puts
$116K
Net Calls
+$215K
Net Calls Change
+$23K

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$21.1M
2
VPC
Vestal Point Capital
New York
+$11.3M
3
BlackRock
BlackRock
New York
+$9.86M
4
ABG
Ally Bridge Group
New York
+$4.48M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$4.36M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$17.9M
2
LCM
Laurion Capital Management
New York
-$4.45M
3
BOCH
Blue Owl Capital Holdings
New York
-$3.52M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$2.14M
5
Goldman Sachs
Goldman Sachs
New York
-$1.45M
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Investment Management
1
T. Rowe Price Investment Management
Maryland
$49.7M +$21.1M +3,934,365 +59%
BG
2
Bellevue Group
Switzerland
$39.7M – – –
NMC
3
NEA Management Company
Maryland
$20.7M – – –
BlackRock
4
BlackRock
New York
$15M +$9.86M +1,836,606 +133%
Vanguard Group
5
Vanguard Group
Pennsylvania
$9.93M +$1.21M +226,324 +12%
VPC
6
Vestal Point Capital
New York
$9.79M +$11.3M +2,100,000 New
TCM
7
Tang Capital Management
California
$7.47M – – –
AG
8
Artal Group
Luxembourg
$4.88M – – –
Millennium Management
9
Millennium Management
New York
$4.68M +$2.46M +458,641 +84%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$3.93M +$2.47M +459,819 +120%
ABG
11
Ally Bridge Group
New York
$3.89M +$4.48M +835,000 New
T. Rowe Price Associates
12
T. Rowe Price Associates
Maryland
$3.79M +$4.36M +813,066 New
Invesco
13
Invesco
Georgia
$3.32M +$3.82M +712,382 New
KCM
14
Kennedy Capital Management
Missouri
$3.28M -$74.6K -13,900 -2%
State Street
15
State Street
Massachusetts
$3.22M +$3.08M +573,348 +490%
SC
16
Stempoint Capital
New York
$3.14M +$3.62M +674,198 New
AAA
17
Affinity Asset Advisors
New York
$3.03M +$3.49M +650,000 New
DCM
18
Driehaus Capital Management
Illinois
$2.82M – – –
ECM
19
ExodusPoint Capital Management
New York
$2.74M +$2.54M +473,052 +409%
BC
20
Boxer Capital
California
$2.36M – – –
UOC
21
UBS O'Connor
Illinois
$1.42M +$251K +46,706 +18%
Connor, Clark & Lunn Investment Management (CC&L)
22
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.34M -$148K -27,656 -9%
TD Asset Management
23
TD Asset Management
Ontario, Canada
$1.24M +$1.05M +195,464 +276%
Renaissance Technologies
24
Renaissance Technologies
New York
$1.23M +$275K +51,300 +24%
BC
25
BIT Capital
Germany
$1.18M -$118K -21,913 -8%
1
2 3 4 5

BDTX Hedge Fund Activity: Q2 2024 in Review

90 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q2 2024, worth a combined $218M — up 9% from $200M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new BDTX positions and 27 closed out — a net gain of 4 holders — while 25 added to existing stakes and 19 trimmed.

The largest buyer was T. Rowe Price Investment Management, adding an estimated $21.1M. The largest seller was RA Capital Management, exiting entirely with an estimated $17.9M sold.

  • 90 institutional investors held Black Diamond Therapeutics (BDTX) as of Q2 2024, up from 88 in Q1 2024.
  • Funds reported $218M of Black Diamond Therapeutics stock for Q2 2024, up 9% quarter-over-quarter.
  • 31 funds opened new Black Diamond Therapeutics positions in Q2 2024 and 27 closed out, a net change of +4 holders.
  • The largest Black Diamond Therapeutics buyer in Q2 2024 was T. Rowe Price Investment Management, an estimated $21.1M added.
  • The largest Black Diamond Therapeutics seller in Q2 2024 was RA Capital Management, an estimated $17.9M sold.

Based on aggregated 13F filings for Q2 2024.